Tamoxifen Citrate CAS 54965-24-1 Safe Steroid Fitness White Nolvadex Powder

Read the Medication Guide provided by your pharmacist before you start using tamoxifen and each time you get a refill. If you have any questions, consult your doctor or pharmacist.

Take this medication by mouth with or without food, usually once or twice daily for 5 years, or as directed by your doctor. Daily dosages greater than 20 milligrams are usually divided in half and taken twice a day, in the morning and evening, or as directed by your doctor. If you are using the liquid, measure the dose carefully using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.

Dosage is based on your medical condition and response to therapy.

Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day.

If you have breast cancer that has spread to other parts of the body, you may experience increased bone/cancer pain and/or disease flare-up as you start taking tamoxifen. In some cases, this may be a sign of a good response to the medication. Symptoms include increased bone pain, increased tumor size, or even new tumors. These symptoms usually disappear quickly. In any case, report these symptoms right away to your doctor.

Since this drug can be absorbed through the skin and lungs, women who are pregnant or who may become pregnant should not handle this medication or breathe the dust from the tablets. (See also Precautions section.)

Tamoxifen Citrate
Class: Antiestrogen

Trade Names
Tamoxifen Citrate
- Tablets, oral 10 mg
- Tablets, oral 20 mg

Pharmacokinetics
Absorption
Tamoxifen C max is 40 ng/mL (range, 35 to 45 ng/mL), T max is approximately 5 h after dosing, and steady state is achieved in approximately 4 wk. N-desmethyl tamoxifen C max is 15 ng/mL (range, 10 to 20 ng/mL). Steady state is achieved in approximately 8 wk.

Metabolism
Tamoxifen is extensively metabolized. The major metabolite is N-desmethyl tamoxifen with biological activity similar to tamoxifen. It is a substrate of CYP-450 3A, 2C9, 2D6, and an inhibitor of P-glycoprotein.

Elimination
Tamoxifen half-life is 5 to 7 days; 65% of a dose is excreted over a 2-wk period, with fecal excretion as the primary route of elimination. N-desmethyl tamoxifen half-life is approximately 14 days.

Special Populations
Hepatic Function Impairment
The effects of reduced liver function have not been determined.

Elderly
The effects of age on the pharmacokinetics of tamoxifen have not been determined.

Children
In pediatric patients, an average steady-state C max and AUC were 187 ng/mL and 4,110 ng•h/mL, respectively, and steady-state C max occurred approximately 8 h after dosing. Cl/F as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients. In the youngest cohort of female pediatric patients (2 to 6 y of age), Cl/F was 2.6-fold higher; in the oldest cohort (7 to 10.9 y of age), Cl/F was approximately 1.9-fold higher.

Gender
The effects of gender on the pharmacokinetics of tamoxifen have not been determined.

Race
The effects of race on the pharmacokinetics of tamoxifen have not been determined.

Indications and Usage

For the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation to reduce the risk of invasive breast cancer; treatment of metastatic breast cancer in women and men; to reduce the incidence of breast cancer in women at high risk of breast cancer.

Unlabeled Uses
Ovulation stimulation in specially selected anovulatory women desiring pregnancy; management and treatment of some types of mastalgia (eg, cyclical); malignant carcinoid tumor and carcinoid syndrome; migraine associated with menstruation; oligozoospermia; McCune-Albright syndrome in female pediatric patients (in combination with other agents); metastatic melanoma; desmoid tumors; gynecomastia.

Contraindications
Hypersensitivity to drug; women who require concomitant coumarin-type anticoagulant therapy or women with a history of deep vein thrombosis (DVT) or pulmonary embolus (PE) (reduction of breast cancer incidence in high-risk women/DCIS only).